Glicron CR30 mg

Glicron CR 30 mg is an oral antidiabetic medicine belonging to the sulphonylurea group. It is specifically indicated for the management of type 2 diabetes mellitus (also known as non-insulin-dependent diabetes mellitus or NIDDM) in adults, in situations where non-pharmacological interventions alone have proven insufficient to achieve adequate blood glucose control.

Primary Indication

• Type 2 diabetes mellitus in adults: Glicron CR 30 mg is indicated when dietary modification, regular physical exercise, and weight reduction alone are not sufficient to maintain blood sugar levels within the recommended target range. It is used as part of a comprehensive diabetes management plan that includes lifestyle interventions, self-monitoring of blood glucose, and regular clinical review.

Use in Combination Therapy

Glicron CR 30 mg may also be prescribed as part of a combination antidiabetic regimen alongside other glucose-lowering agents, including:

• Metformin: One of the most common combinations in type 2 diabetes management, providing complementary mechanisms of insulin secretion stimulation (Glicron CR 30 mg) and hepatic glucose output reduction (Metformin).
• Alpha-glucosidase inhibitors (e.g., acarbose): Reduce postprandial blood glucose by slowing carbohydrate digestion.
• Thiazolidinediones (e.g., pioglitazone): Improve insulin sensitivity in peripheral tissues.
• DPP-4 inhibitors (e.g., sitagliptin, vildagliptin): Enhance incretin-mediated insulin secretion in a glucose-dependent manner.
• GLP-1 receptor agonists (e.g., liraglutide, exenatide): Stimulate insulin secretion and suppress glucagon in a glucose-dependent manner.
• Insulin: In patients with progressive beta-cell failure, Glicron CR 30 mg may be used alongside basal insulin therapy under physician supervision.

Glicron CR 30 mg is not used in type 1 diabetes mellitus (insulin-dependent), diabetic ketoacidosis, or in children. Always use under the guidance of a registered physician who will determine the most appropriate treatment plan based on individual patient factors.

Glicron CR 30 mg is a second-generation sulphonylurea oral hypoglycaemic agent with a well-established mechanism for reducing blood glucose in patients with type 2 diabetes mellitus. Beyond its primary glucose-lowering action, it also possesses potentially beneficial haematological and vascular properties that distinguish it from first-generation sulphonylureas.

Mechanism of Action

• Stimulation of pancreatic insulin secretion: Glicron CR 30 mg binds to specific sulphonylurea receptors (SUR1) on the ATP-sensitive potassium channels (K_ATP channels) located on pancreatic beta (β) cell membranes. This binding closes the K_ATP channels, leading to membrane depolarisation. The resulting change in membrane potential opens voltage-dependent calcium channels, facilitating the influx of calcium ions (Ca²⁺) into the β-cell. The rise in intracellular calcium triggers the exocytosis of insulin-containing secretory granules, thereby increasing insulin secretion into the bloodstream. This mechanism is the primary driver of Glicron CR 30 mg's blood glucose-lowering effect.
• Reduction of hepatic glucose output: Glicron CR 30 mg decreases the rate of hepatic glucose production (gluconeogenesis and glycogenolysis), reducing the fasting glucose load delivered to the circulation and contributing to lower fasting blood glucose levels.
• Improvement of peripheral insulin sensitivity: To a lesser extent, Glicron CR 30 mg may improve the sensitivity of peripheral tissues (particularly skeletal muscle and adipose tissue) to the action of insulin, enhancing glucose uptake and utilisation.

Additional Pharmacological Properties

• Antioxidant and free radical scavenging activity: Glicron CR 30 mg possesses a unique azabicyclo-octyl ring structure that confers antioxidant properties. This reduces oxidative stress in vascular tissues — a major contributor to the development of diabetic micro- and macrovascular complications.
• Antiplatelet and haematological effects: Glicron CR 30 mg inhibits platelet aggregation and adhesion, and reduces platelet reactivity. This is clinically significant as platelet hyperactivity in diabetes contributes to thrombotic events and progression of microvascular disease. Unlike some older sulphonylureas, Glicron CR 30 mg has relatively selective affinity for pancreatic SUR1 over cardiac SUR2A receptors, which may result in fewer adverse cardiovascular effects.
• Modified release (MR) formulation benefits: The modified-release (MR/XR) formulations of Glicron CR 30 mg (30 mg and 60 mg) provide a more gradual, sustained release of the drug throughout the day following a single morning dose, producing a smoother insulin secretion profile that more closely mirrors the physiological insulin response and reduces the risk of hypoglycaemia compared to standard-release formulations.

Pharmacokinetics

• Absorption: Glicron CR 30 mg is well absorbed from the gastrointestinal tract after oral administration, with nearly complete bioavailability. For MR formulations, absorption is slower and more prolonged, maintaining therapeutic plasma concentrations over 24 hours.
• Protein binding: Glicron CR 30 mg is extensively bound to plasma proteins (approximately 95%), primarily to albumin.
• Metabolism: Glicron CR 30 mg is extensively metabolised in the liver. Its metabolites are pharmacologically inactive, meaning they do not contribute to hypoglycaemic effects — an important safety advantage in patients with renal impairment, as inactive metabolites pose a lower risk of accumulation-related hypoglycaemia.
• Elimination: The drug and its metabolites are excreted primarily in the urine (approximately 60–70%), with the remainder eliminated in the faeces. The plasma elimination half-life is approximately 10 to 12 hours for standard-release tablets and effectively 24 hours for MR formulations.

Glicron CR 30 mg interacts with a wide range of commonly used medications. These interactions can either strengthen its blood glucose-lowering effect (increasing the risk of hypoglycaemia) or weaken it (increasing the risk of hyperglycaemia). Always inform your physician and pharmacist of all medications, herbal preparations, and supplements you are currently taking before starting Glicron CR 30 mg.

Drugs That May Increase the Blood Glucose-Lowering Effect (Risk of Hypoglycaemia)

• Other antidiabetic agents: Metformin, GLP-1 receptor agonists, insulin, DPP-4 inhibitors, and other oral antidiabetics may have an additive glucose-lowering effect when combined with Glicron CR 30 mg. Careful blood glucose monitoring and dose adjustment are essential.
• Antibiotics — sulphonamides and clarithromycin: These agents can displace Glicron CR 30 mg from plasma protein binding sites or inhibit its metabolism, increasing free drug levels and the risk of hypoglycaemia.
• Beta-blockers: May mask the tachycardia and tremor symptoms of hypoglycaemia, making it more difficult for the patient to recognise a hypoglycaemic episode. Beta-blockers may also impair glucose counter-regulation.
• ACE inhibitors (e.g., captopril, enalapril): Used for hypertension and heart failure. These agents may enhance insulin sensitivity and increase hypoglycaemic risk when combined with Glicron CR 30 mg.
• Antifungal agents — miconazole, fluconazole: These inhibit the hepatic CYP2C9 enzyme responsible for Glicron CR 30 mg metabolism, leading to significantly elevated plasma Glicron CR 30 mg levels and a high risk of severe hypoglycaemia. Miconazole is in fact contraindicated with Glicron CR 30 mg.
• H2-receptor antagonists (e.g., cimetidine, ranitidine): Used for stomach ulcers. Cimetidine in particular may inhibit Glicron CR 30 mg metabolism.
• Monoamine oxidase inhibitors (MAOIs): Used for depression. MAOIs can potentiate the hypoglycaemic effect of sulphonylureas.
• Non-steroidal anti-inflammatory drugs (NSAIDs): Phenylbutazone and ibuprofen may displace Glicron CR 30 mg from protein binding, increasing free drug concentrations and hypoglycaemic risk.
• Alcohol-containing preparations: Alcohol can potentiate the hypoglycaemic effect of Glicron CR 30 mg and may also trigger a disulfiram-like reaction. Patients should avoid alcohol during Glicron CR 30 mg treatment.

Drugs That May Reduce the Blood Glucose-Lowering Effect (Risk of Hyperglycaemia)

• Chlorpromazine and other antipsychotics: At high doses, chlorpromazine reduces insulin release, antagonising the glucose-lowering effect of Glicron CR 30 mg.
• Corticosteroids (e.g., prednisolone, dexamethasone): These agents cause significant hyperglycaemia by promoting gluconeogenesis and insulin resistance. Patients on corticosteroids may require increased Glicron CR 30 mg doses or transition to insulin therapy.
• Beta-2 adrenergic agonists (e.g., intravenous salbutamol, ritodrine, terbutaline): Used in asthma management and to suppress premature labour. These agents stimulate glycogenolysis and reduce insulin secretion, causing hyperglycaemia.
• Danazol: Used for breast disorders, heavy menstrual bleeding, and endometriosis. Danazol has diabetogenic properties and may impair glycaemic control with Glicron CR 30 mg.
• St John's Wort (Hypericum perforatum): This commonly used herbal supplement induces hepatic CYP enzymes, accelerating Glicron CR 30 mg metabolism and reducing its plasma concentrations and antidiabetic efficacy. Patients must be strongly advised to disclose all herbal supplement use.

Bidirectional Blood Glucose Disturbance

• Fluoroquinolone antibiotics (e.g., ciprofloxacin, levofloxacin): Can cause both hypoglycaemia and hyperglycaemia unpredictably when used concurrently with Glicron CR 30 mg, particularly in elderly patients. Enhanced blood glucose monitoring is essential when this combination is necessary.

Effect of Glicron CR 30 mg on Other Drugs

• Warfarin (anticoagulants): Glicron CR 30 mg may inhibit the metabolism of warfarin, increasing its plasma concentration and enhancing the anticoagulant effect. This increases the risk of bleeding. Regular INR monitoring is essential in patients receiving both drugs.

Food and Drink Interactions

• Food: Glicron CR 30 mg should be taken with food. Taking it on an empty stomach significantly increases the risk of hypoglycaemia.
• Alcohol: Alcohol can unpredictably alter blood glucose control and potentiate the hypoglycaemic effect of Glicron CR 30 mg. Alcohol consumption is not recommended during treatment.

Like all medicines, Glicron CR 30 mg can cause side effects, although not all patients experience them. Most side effects are manageable, but some require prompt medical attention. Patients and caregivers should be familiar with the following adverse effects:

Hypoglycaemia (Low Blood Sugar) — Most Common and Clinically Important

• The most frequently observed and clinically significant adverse effect of Glicron CR 30 mg is hypoglycaemia (abnormally low blood glucose). It is most likely to occur if meals are skipped, if the dose is too high, if physical activity is significantly increased without adjusting the dose, or if alcohol is consumed.
• Early warning symptoms: Headache, intense hunger, nausea, cold sweats, clamminess, shakiness/tremor, palpitations, anxiety, dizziness, weakness, and difficulty concentrating.
• Severe hypoglycaemia symptoms: Confusion, delirium, convulsions, loss of consciousness, shallow breathing, slowed heartbeat, and coma. Severe or prolonged hypoglycaemia is a medical emergency requiring immediate intervention.
• Patients should always carry a rapid-acting sugar source (glucose tablets, sugar cubes, or a sugary drink) and know how to act if hypoglycaemia occurs. If symptoms do not respond to sugar intake, or if the patient is unconscious, emergency medical services must be contacted immediately.

Gastrointestinal Side Effects

• Abdominal pain, nausea, vomiting, indigestion (dyspepsia), diarrhoea, and constipation may occur. These effects are significantly reduced when Glicron CR 30 mg is taken with a meal, as recommended.

Liver (Hepatic) Disorders

• Isolated reports of abnormal liver function tests and hepatic enzyme elevation have been reported. In rare cases, this may manifest as jaundice (yellowing of the skin and whites of the eyes), indicating cholestatic liver injury. If jaundice develops, discontinue Glicron CR 30 mg immediately and seek medical attention. Symptoms generally resolve after discontinuation.

Skin (Dermatological) Disorders

• Skin reactions including rash, redness, itching, urticaria (hives), and blistering have been reported.
• Angioedema: Rapid and potentially life-threatening swelling of the eyelids, face, lips, mouth, tongue, or throat that may cause difficulty breathing. Seek emergency care immediately if angioedema is suspected.
• Rarely, rash may progress to widespread blistering and peeling of the skin (Steven-Johnson Syndrome or Toxic Epidermal Necrolysis). Discontinue Glicron CR 30 mg immediately and seek urgent specialist medical care if this occurs.
• Rarely, severe hypersensitivity reactions resembling drug reaction with eosinophilia and systemic symptoms (DRESS) have been reported — initially presenting as flu-like symptoms and facial rash, progressing to an extended rash with high fever.

Blood (Haematological) Disorders

• Decreases in blood cell counts have been reported, including reduction in platelets (thrombocytopenia), red blood cells (anaemia), and white blood cells (leucopenia) — collectively termed as blood dyscrasias.
• Symptoms include paleness, unusual bruising or prolonged bleeding, sore throat, and persistent fever. These effects typically resolve when treatment is discontinued.
• Rare cases of haemolytic anaemia have been reported in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency. Patients with known or suspected G6PD deficiency should consult their physician before taking Glicron CR 30 mg.
• Hyponatraemia (low blood sodium) has been reported as a class effect of sulphonylureas.

Eye (Ophthalmic) Disorders

• Transient visual disturbances may occur, particularly at the start of treatment. These are caused by fluctuations in blood glucose levels affecting the lens of the eye and typically resolve as blood sugar stabilises. Report any persistent or significant visual changes to your physician.

If you experience any unexpected or severe side effects while taking Glicron CR 30 mg, contact your physician or pharmacist immediately.

Pregnancy

Glicron CR 30 mg is not recommended for use during pregnancy. If you are pregnant, think you may be pregnant, or are planning to become pregnant, you must inform your physician before taking or continuing Glicron CR 30 mg.

Uncontrolled blood glucose during pregnancy is associated with an increased risk of foetal malformations, macrosomia (abnormally large baby), neonatal hypoglycaemia, perinatal mortality, and maternal complications. For this reason, optimal blood glucose management throughout pregnancy is essential.

Sulphonylureas, including Glicron CR 30 mg, can cross the placenta and may stimulate fetal pancreatic β-cells, causing neonatal hypoglycaemia. The current standard of care for diabetes management in pregnancy is insulin therapy, which does not cross the placental barrier and provides more precise and titratable glycaemic control. Women planning a pregnancy who are currently taking Glicron CR 30 mg should discuss transitioning to insulin before conception or as early in pregnancy as possible, under the supervision of their physician and obstetric team.

Lactation (Breastfeeding)

Glicron CR 30 mg must not be used while breastfeeding. It is unknown whether Glicron CR 30 mg or its metabolites are excreted into human breast milk in clinically significant quantities. Given the pharmacological mechanism of the drug — stimulating insulin secretion — there is a theoretical risk of inducing hypoglycaemia in the nursing infant, who has no clinical need for blood glucose reduction and whose immature counter-regulatory mechanisms make hypoglycaemia particularly dangerous.

Women with type 2 diabetes who wish to breastfeed should discuss alternative blood glucose management options with their physician. Insulin is generally preferred during lactation as it is not expected to be excreted into breast milk at pharmacologically meaningful concentrations.

The following precautions must be carefully observed by all patients receiving Glicron CR 30 mg therapy to ensure safe and effective diabetes management:

Adherence to the Complete Treatment Plan

• Glicron CR 30 mg alone is not sufficient to manage type 2 diabetes optimally. Patients must also comply fully with the prescribed dietary plan, engage in regular physical activity, and achieve and maintain a healthy body weight. Medication works best as part of a holistic diabetes management approach.

Blood Glucose and HbA1c Monitoring

• Regular monitoring of fasting and postprandial blood glucose levels, and periodic measurement of glycated haemoglobin (HbA1c), is mandatory during Glicron CR 30 mg treatment. This allows timely dose adjustment and assessment of long-term glycaemic control.
• In the first few weeks of treatment, the risk of hypoglycaemia is increased. More frequent blood glucose monitoring and close medical supervision are particularly important during this period.

Recognising and Managing Hypoglycaemia

• Patients must be fully educated about the symptoms of hypoglycaemia, how to treat it (consuming 15–20 g of fast-acting sugar), and when to seek emergency medical care.
• Always carry a rapid-acting source of sugar (glucose tablets, sugar cubes, or a sugary drink). Artificial sweeteners do not treat hypoglycaemia.
• Hypoglycaemia is more likely in patients who: skip or delay meals, fast, are malnourished, significantly increase physical activity without adjusting carbohydrate intake, drink alcohol (especially without eating), take other hypoglycaemic agents, take an excessive dose, or have thyroid, pituitary, or adrenal gland disorders.
• In the elderly and in patients taking beta-blockers or central nervous system agents, the warning signs of hypoglycaemia may be absent, blunted, or develop very slowly. These patients require particularly vigilant monitoring.

Recognising Hyperglycaemia

• Symptoms of high blood sugar (hyperglycaemia) — including excessive thirst, frequent urination, dry mouth, dry and itchy skin, skin infections, and tiredness — may occur when Glicron CR 30 mg has not yet achieved sufficient blood glucose control, when the treatment plan has not been followed, when St John's Wort is taken concurrently, or during acute stress situations. Report persistent hyperglycaemia to your physician promptly.

Stressful Situations and Illness

• During periods of significant physical or psychological stress — including serious infections, trauma, accidents, fever, or planned surgical operations — blood glucose control may deteriorate significantly. Your physician may temporarily switch you to insulin therapy during these periods to maintain safe blood glucose levels.

Fluoroquinolone Antibiotics

• Blood glucose disturbances (both hypoglycaemia and hyperglycaemia) can occur when fluoroquinolone antibiotics (e.g., ciprofloxacin, levofloxacin) are prescribed simultaneously with Glicron CR 30 mg, particularly in elderly patients. Enhanced blood glucose monitoring is essential during the course of fluoroquinolone treatment.

G6PD Deficiency

• Patients with a family history of or known glucose-6-phosphate dehydrogenase (G6PD) deficiency are at risk of haemolytic anaemia when taking sulphonylureas. Consult your physician before starting Glicron CR 30 mg if you have this condition.

Driving and Operating Machinery

• Hypoglycaemia or hyperglycaemia, and associated visual disturbances, can significantly impair concentration and reaction time, making driving or operating machinery dangerous. Patients must be warned about this risk and advised not to drive if they experience frequent hypoglycaemic episodes or have reduced awareness of hypoglycaemia symptoms.

Lactose Content

• Glicron CR 30 mg tablets contain lactose as an excipient. Patients with known lactose intolerance or galactose malabsorption should inform their physician before taking this medicine.

Use in Children

• Glicron CR 30 mg is not recommended for use in children due to lack of safety and efficacy data in the paediatric population.

Glicron CR 30 mg overdose results in hypoglycaemia — an abnormally and potentially dangerously low blood glucose level — due to excessive, prolonged stimulation of pancreatic insulin secretion. Overdose can occur through accidental ingestion (particularly in children), deliberate self-administration of excess tablets, or through pharmacokinetic interactions with other drugs that dramatically increase Glicron CR 30 mg plasma levels.

Symptoms of Overdose (Hypoglycaemia)

• Mild to moderate: Headache, intense hunger, nausea, vomiting, anxiety, cold and clammy sweating, trembling, palpitations, dizziness, weakness, poor concentration, visual disturbances, and irritability.
• Severe: Profound confusion, delirium, aggressive behaviour, convulsions, loss of consciousness, coma, shallow breathing, and slowed heartbeat. These are medical emergencies.

Immediate Management of Mild to Moderate Overdose (Conscious Patient)

• Administer 15 to 20 grams of fast-acting carbohydrate immediately — equivalent to 4 to 6 glucose tablets, or a glass of fruit juice or regular (non-diet) sugary drink, followed by a substantial meal or snack to prevent recurrence.
• Monitor blood glucose closely and regularly for several hours after the episode, as hypoglycaemia can recur due to the prolonged action of Glicron CR 30 mg.
• Contact a physician promptly even if the patient initially appears to recover.

Management of Severe Overdose (Unconscious Patient or Unresponsive to Oral Treatment)

• Do not give food or drink to an unconscious patient — there is a risk of aspiration.
• Call emergency medical services immediately.
• Hospital management involves intravenous administration of concentrated glucose solution (e.g., 50 ml of 50% dextrose) followed by a continuous IV glucose infusion to maintain blood glucose levels.
• Glucagon injection may be used if IV access is not immediately available, particularly for out-of-hospital emergency management.
• Close monitoring of blood glucose is required for at least 24 to 48 hours after severe hypoglycaemia, as recurrence is likely due to the prolonged half-life of Glicron CR 30 mg.

Prevention

• Always store Glicron CR 30 mg out of the reach of children.
• Ensure a pre-informed person is aware of how to call for emergency help and how to recognise hypoglycaemia.
• Never adjust the dose without consulting your physician.

• Store below 30°C: Glicron CR 30 mg tablets should be stored at a controlled room temperature not exceeding 30°C. Avoid storing in areas subject to high temperatures, such as inside a vehicle, near a stove or oven, or in direct sunlight.
• Keep in a dry place: Protect from moisture and humidity. Do not store in bathrooms or near kitchen sinks where humidity levels are high, as moisture can compromise tablet integrity and accelerate degradation of the active ingredient.
• Protect from light: Store Glicron CR 30 mg tablets in the original opaque blister packaging or container. Keep away from direct sunlight and prolonged exposure to artificial fluorescent lighting.
• Keep out of the reach and sight of children: All formulations of Glicron CR 30 mg must be stored in a secure location completely inaccessible to children. A single tablet contains enough drug to cause severe, life-threatening hypoglycaemia in a child. If a child accidentally ingests Glicron CR 30 mg, seek emergency medical care immediately.
• Check the expiry date: Do not use Glicron CR 30 mg after the expiry date printed on the carton and blister packaging. The expiry date refers to the last day of the stated month. Using expired medication may result in reduced efficacy or increased risk of side effects.
• Proper disposal: Do not dispose of medicines via wastewater (sink or toilet) or by placing them in household refuse, as this can contaminate water supplies and the environment. Ask your pharmacist about the appropriate medicine disposal programme available in your area.
• Modified-release tablet handling: Do not remove the MR tablet from its blister until immediately before taking it, as exposure to air and humidity can alter the modified-release coating and affect drug release kinetics.

Renal Impairment

Glicron CR 30 mg should be used with caution in patients with mild to moderate renal impairment. Since Glicron CR 30 mg's metabolites are pharmacologically inactive, it offers a relative safety advantage over other sulphonylureas (such as glibenclamide) whose active metabolites can accumulate in renal failure and cause prolonged severe hypoglycaemia. However, Glicron CR 30 mg is contraindicated in severe renal impairment (eGFR <30 ml/min/1.73m²) due to the risk of altered drug clearance and hypoglycaemia. Regular renal function monitoring is advised during long-term therapy. Close glucose monitoring is essential in all patients with any degree of renal impairment.

Hepatic Impairment

Since Glicron CR 30 mg is extensively metabolised in the liver, significant hepatic impairment can markedly increase its plasma concentrations and prolong its duration of action, leading to a substantially elevated risk of hypoglycaemia. Glicron CR 30 mg is contraindicated in severe hepatic impairment. In patients with mild to moderate liver disease, use with caution and with more frequent blood glucose monitoring. Hepatic function tests should be performed periodically during treatment.

Geriatric Use (Elderly Patients)

Elderly patients with type 2 diabetes are at increased risk of hypoglycaemia for several reasons: reduced renal clearance of the drug, irregular meal patterns, reduced glycogen reserves, comorbid conditions, and polypharmacy. Additionally, the warning signs of hypoglycaemia (particularly adrenergic symptoms like tremor and tachycardia) may be masked or blunted in the elderly, delaying recognition and treatment. The modified-release (MR) formulation of Glicron CR 30 mg may be preferable in elderly patients due to its more gradual, smoother insulin stimulation profile and lower hypoglycaemia risk compared to standard-release tablets. Close blood glucose monitoring and conservative dosing initiation are recommended in this population.

Paediatric Use

Glicron CR 30 mg is not recommended for use in children. There is a lack of safety and efficacy data in the paediatric population, and Glicron CR 30 mg is contraindicated in type 1 diabetes (juvenile-onset diabetes), which represents the majority of diabetes cases presenting in childhood. Paediatric diabetes management should be directed by a specialist paediatric diabetologist.

G6PD Deficiency

Patients with hereditary glucose-6-phosphate dehydrogenase (G6PD) deficiency, an X-linked genetic condition affecting red blood cell integrity, may develop haemolytic anaemia when taking sulphonylurea drugs including Glicron CR 30 mg. This occurs due to oxidative stress on G6PD-deficient red blood cells. Patients with known or suspected G6PD deficiency must inform their physician before starting Glicron CR 30 mg. Alternative antidiabetic treatments should be considered in this population.

Patients with Adrenal, Pituitary, or Thyroid Disorders

Functional disorders of the adrenal cortex, pituitary gland, or thyroid gland can significantly alter glucose counter-regulation and blood glucose homeostasis. Patients with these endocrine disorders are at increased risk of abnormal blood glucose responses to Glicron CR 30 mg and require closer monitoring and more careful dose titration.